Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2017 Q2- Text added to 2017 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
administered, affinity, America, ARMO, ARROW, ASH, Aurobindo, avian, baseline, bevacizumab, biologic, BioMed, Bioscience, body, Breast, Bryxta, Cadila, Caribbean, CASI, Cempra, Central, cholesterol, complementary, concomitant, conserved, Contract, contracted, CRO, Crystal, Daiichi, epitope, ER, esaxerenone, essential, Estrogen, Eurofarma, expression, fourth, gene, HanAll, Harbour, HDL, Hematology, hemoglobin, HuMab, hypertension, Ia, idiopathic, immunoglobulin, Immunoprecise, Inborn, incomplete, India, ITP, Japanese, laboratory, launched, LDL, lt, mg, moderate, Molecular, North, OmniChicken, online, Organization, Pharma, pivotal, placebo, PPD, pressure, priority, robust, Sankyo, similarly, sNDA, Tizona, twenty, USA, worsening, WuXi
Valuein 2017 Q2 filing- Value in 2017 Q3 filing
Original filings
Filing view